<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11615">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01927406</url>
  </required_header>
  <id_info>
    <org_study_id>26654</org_study_id>
    <nct_id>NCT01927406</nct_id>
  </id_info>
  <brief_title>The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.</brief_title>
  <official_title>The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the potential secondary beneficial effect of
      prostaglandin analogues (PA) treatment  in thyroid eye disease (TED) patients. This study
      aims to determine if PA would change the course of  the orbitopathy in TED patients by
      altering the progression of the common features of TED, including fatty hypertrophy,
      proptosis, eyelid retraction and optic nerve compression. The eyes with thyroid eye disease
      and elevated intraocular pressure will be randomised to the PA treatment and the other eye
      will serve as a control eye and will be treated with Timolol.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Change from baseline in appearance of facial periorbital region at 12 months.</measure>
    <time_frame>0 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Hertel exophthalmometry at 12 and 24 months.</measure>
    <time_frame>0 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in intraocular pressure at 12 and 24 months.</measure>
    <time_frame>0 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in appearance of facial periorbital region at 24 months.</measure>
    <time_frame>0 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Thyroid Eye Disease</condition>
  <condition>Ocular Hypertension</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Prostaglandin Analog vs Timolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, with thyroid eye disease and increased intraocular pressure in both eyes, prostaglandin analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one - randomised eye. Timolol 0.5% eye drop will be administered topically in second, control eye, two times a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prostaglandin Analog</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, with thyroid eye disease and increased intraocular pressure in only one eye Prostaglandin Analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one, affected eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prostaglandin Analog</intervention_name>
    <description>The first choice drug from group of Prostaglandin Analogues will be bimatoprost, if patient will suffer from any side effect of this drug another drug from this group will be administer. If patient turned out to cannot tolerate the prostaglandin analog therapy then the exclusion criteria will be met.</description>
    <arm_group_label>Prostaglandin Analog vs Timolol</arm_group_label>
    <arm_group_label>Prostaglandin Analog</arm_group_label>
    <other_name>Bimatoprost</other_name>
    <other_name>Travoprost Z</other_name>
    <other_name>Tafluprost</other_name>
    <other_name>Latanoprost</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol</intervention_name>
    <description>Timolol topical eye drop will be administered in Prostaglandin Analog vs Timolol arm only, in patients with elevated intraocular pressure in both eyes.</description>
    <arm_group_label>Prostaglandin Analog vs Timolol</arm_group_label>
    <other_name>Timolol maleate 0.5%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mild or moderate to severe thyroid eye disease in one or both eyes

          -  age &gt; 18 years

          -  informed consent

          -  intraocular pressure &gt; 21 mmHg or glaucoma suspect or glaucoma diagnosed in one or
             both eyes

          -  not on current prostaglandin analog intraocular pressure lowering therapy

        Exclusion Criteria:

          -  sight threatening thyroid eye disease

          -  children &lt; 18 years old

          -  patients that are not compliant with treatment or follow-up

          -  patients already on prostaglandin analog treatment

          -  patients that undergo cosmetic periocular procedures during the study will be
             excluded from further follow up

          -  patients that cannot tolerate prostaglandin analog treatment.

          -  patients with bilateral thyroid eye disease and elevated intraocular pressures that
             cannot tolerate treatment with timolol or an alternative intraocular pressure
             lowering medication such as trusopt, combigan, cosopt.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea L. Kossler, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Bartlett</last_name>
    <phone>650-724-9259</phone>
    <email>bbartlet@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara Bartlett</last_name>
      <phone>650-724-9259</phone>
      <email>bbartlet@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 19, 2013</lastchanged_date>
  <firstreceived_date>August 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Andrea L Kossler</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Thyroid Eye Disease</keyword>
  <keyword>Graves' Disease</keyword>
  <keyword>Prostaglandin Analogues</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Travoprost</mesh_term>
    <mesh_term>Bimatoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
